Abstract
The inbuilt 2-N-hydroxy-1-oxo-3-carboxylic acid of isoquinolone was designed as pyrophosphate mimic for hepatitis C NS5B polymerase. Various 2-hydroxy-1-oxo-1,2-dihydroisoquinoline-3-carboxylic acid derivatives 11a-p were synthesized and evaluated as HCV NS5B polymerase inhibitors. Compound 11c exhibited moderate inhibitory potency based on the inorganic pyrophosphate generation (IC50 = 9.5 μM) and based on NTP incorporation by NS5B enzyme (IC50 = 5.9 μM). Compound 11c demonstrated antiviral activity (EC50 = 15.7 μM) and good selectivity in HCV genotype 1b replicon Ava.5 cells. Compound 11c reduced the interaction of NTP to NS5B polymerase. Docking model showed that 11c situated in similar orientation to the bound uridine triphosphate in the active site of NS5B polymerase. As a result, 2-hydroxy-1-oxo-1,2-dihydroisoquinoline-3-carboxylic acid was disclosed as a novel inbuilt γ-keto-acid pharmacophore for HCV NS5B polymerase inhibitors.
Keywords: Hepatitis C virus, non-structural protein 5B (NS5B) polymerase, α, γ-diketo acid, β-N-Hydroxy-γ-keto-acid, pyrophosphate mimic, metal chelation, structure-activity relationship, active site inhibitors, lead compound, pharmacophore
Current Medicinal Chemistry
Title: 2-Hydroxy-1-oxo-1,2-dihydroisoquinoline-3-carboxylic Acid with Inbuilt β-N-Hydroxy-γ-keto-acid Pharmacophore as HCV NS5B Polymerase Inhibitors
Volume: 19 Issue: 4
Author(s): R. R. Deore, G. S. Chen, C. -S. Chen, P. -T. Chang, M. -H. Chuang, T. -R. Chern, H. -C. Wang and J. -W. Chern
Affiliation:
Keywords: Hepatitis C virus, non-structural protein 5B (NS5B) polymerase, α, γ-diketo acid, β-N-Hydroxy-γ-keto-acid, pyrophosphate mimic, metal chelation, structure-activity relationship, active site inhibitors, lead compound, pharmacophore
Abstract: The inbuilt 2-N-hydroxy-1-oxo-3-carboxylic acid of isoquinolone was designed as pyrophosphate mimic for hepatitis C NS5B polymerase. Various 2-hydroxy-1-oxo-1,2-dihydroisoquinoline-3-carboxylic acid derivatives 11a-p were synthesized and evaluated as HCV NS5B polymerase inhibitors. Compound 11c exhibited moderate inhibitory potency based on the inorganic pyrophosphate generation (IC50 = 9.5 μM) and based on NTP incorporation by NS5B enzyme (IC50 = 5.9 μM). Compound 11c demonstrated antiviral activity (EC50 = 15.7 μM) and good selectivity in HCV genotype 1b replicon Ava.5 cells. Compound 11c reduced the interaction of NTP to NS5B polymerase. Docking model showed that 11c situated in similar orientation to the bound uridine triphosphate in the active site of NS5B polymerase. As a result, 2-hydroxy-1-oxo-1,2-dihydroisoquinoline-3-carboxylic acid was disclosed as a novel inbuilt γ-keto-acid pharmacophore for HCV NS5B polymerase inhibitors.
Export Options
About this article
Cite this article as:
R. Deore R., S. Chen G., -S. Chen C., -T. Chang P., -H. Chuang M., -R. Chern T., -C. Wang H. and -W. Chern J., 2-Hydroxy-1-oxo-1,2-dihydroisoquinoline-3-carboxylic Acid with Inbuilt β-N-Hydroxy-γ-keto-acid Pharmacophore as HCV NS5B Polymerase Inhibitors, Current Medicinal Chemistry 2012; 19 (4) . https://dx.doi.org/10.2174/092986712798918833
DOI https://dx.doi.org/10.2174/092986712798918833 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Regulatory T Cells and Skin Tumors
Recent Patents on Inflammation & Allergy Drug Discovery Role of the Gut Microbiota in Age-Related Chronic Inflammation
Endocrine, Metabolic & Immune Disorders - Drug Targets Chromatin Remodelling: Distinct Molecular Events During Differentiation and Activation of T Cells
Current Immunology Reviews (Discontinued) Role for Poly(ADP-ribose) Polymerase Activation in Diabetic Nephropathy, Neuropathy and Retinopathy
Current Vascular Pharmacology Chemokines and Atherosclerotic Plaque Progression: Towards Therapeutic Targeting?
Current Pharmaceutical Design Rhodanine as a Privileged Scaffold in Drug Discovery
Current Medicinal Chemistry Recent Advances in the Development of Anti-Infective Prophylactic and/or Therapeutic Agents Based on Toll-Like Receptor (TLRs)
Recent Patents on Anti-Infective Drug Discovery Central Self - Tolerance by Thymic Presentation of Self - Antigens and Autoimmunity
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Engineering of Conotoxins for the Treatment of Pain
Current Pharmaceutical Design Pharmacogenetics, Target Molecules, and Biological Anti-Rheumatic Drugs in Autoimmune/Chronic Inflammatory Rheumatic Diseases
Current Pharmacogenomics Protein-Tyrosine Kinases and Adaptor Proteins in FcεRI-Mediated Signaling in Mast Cells
Current Molecular Medicine Patent Selections
Recent Patents on Cardiovascular Drug Discovery Stat3 Orchestrates Tumor Development and Progression: The Achilles Heel of Head and Neck Cancers?
Current Cancer Drug Targets Isolation and Boactivities of Furfuran Type Lignan Compounds from Edible Plants
Recent Patents on Food, Nutrition & Agriculture Cells and Mediators of Inflammation in Acute Pancreatitis
Clinical Anti-Inflammatory & Anti-Allergy Drugs (Discontinued) Update on the Biologic Role of the Vitamin D Endocrine System
Current Vascular Pharmacology New Patents of Fixed Combinations of Nasal Antihistamines and Corticosteroids in Allergic Rhinitis
Recent Patents on Inflammation & Allergy Drug Discovery Relationship Between HIV-RNA Load in Blood and Semen in Antiretroviral-Naive and Experienced Men and Effect of Asymptomatic Sexually Transmissible Infections
Current HIV Research Biological Relevance of Lysophospholipids and Green Solutions for Their Synthesis
Current Organic Chemistry A Summary of Electrospun Nanofibers as Drug Delivery System: Drugs Loaded and Biopolymers Used as Matrices
Current Drug Delivery